COMP <GO>
PRPO vs HBIO // REVENUE GROWTH (YOY)
Precipio Inc. (NASDAQ) VS. Harvard Bioscience Inc. (NASDAQ) • 15-METRIC TALLY: PRPO 5
— HBIO 4
▲ REVENUE GROWTH (YOY) LEADER: PRPO
LAST: $19.35 (+3.59%) • MKT CAP: $34.6M
revenue-growth
30.50%
LAST: $8.80 (+4.51%) • MKT CAP: $40.1M
revenue-growth
-8.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRPO VS. HBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRPO | HBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.20% | 57.70% | -13.50 | HBIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.90% | -35.00% | +27.10 | PRPO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.04% | 13.66% | -12.62 | HBIO | /fcf-yield <GO> |
| Operating Margin | -5.00% | -56.10% | +51.10 | PRPO | /operating-margins <GO> |
| Net Profit Margin | -1.50% | -60.00% | +58.50 | PRPO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 30.50% | -8.10% | +38.60 | PRPO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | PRPO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.4 | 68.8 | -43.39 | HBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.6M | $40.1M | -$5.4M | HBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRPO REV | HBIO REV | PRPO GROSS % | HBIO GROSS % | PRPO FCF | HBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $24.2M | $86.5M | 44.2% | 57.7% | $359.0K | $5.5M |
| FY 2024 | $18.6M | $94.1M | 40.7% | 58.2% | $216.0K | -$1.2M |
| FY 2023 | $15.4M | $112.3M | — | — | -$3.6M | $14.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRPO // BETA —
HBIO // BETA —